Moving tuberculosis vaccines from theory to practice

Research output: Contribution to journal › Review › Research › peer-review

Standard

Moving tuberculosis vaccines from theory to practice. / Andersen, Peter; Scriba, Thomas J.

In: Nature Reviews. Immunology, Vol. 19, 2019, p. 550–562.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Andersen, P & Scriba, TJ 2019, 'Moving tuberculosis vaccines from theory to practice', Nature Reviews. Immunology, vol. 19, pp. 550–562. https://doi.org/10.1038/s41577-019-0174-z

APA

Andersen, P., & Scriba, T. J. (2019). Moving tuberculosis vaccines from theory to practice. Nature Reviews. Immunology, 19, 550–562. https://doi.org/10.1038/s41577-019-0174-z

Vancouver

Andersen P, Scriba TJ. Moving tuberculosis vaccines from theory to practice. Nature Reviews. Immunology. 2019;19:550–562. https://doi.org/10.1038/s41577-019-0174-z

Author

Andersen, Peter ; Scriba, Thomas J. / Moving tuberculosis vaccines from theory to practice. In: Nature Reviews. Immunology. 2019 ; Vol. 19. pp. 550–562.

Bibtex

@article{6810b01cc1074f098d7f79325b211391,
title = "Moving tuberculosis vaccines from theory to practice",
abstract = "Tuberculosis (TB) vaccine research has reached a unique point in time. Breakthrough findings in both the basic immunology of Mycobacterium tuberculosis infection and the clinical development of TB vaccines suggest, for the first time since the discovery of the Mycobacterium bovis bacillus Calmette–Gu{\'e}rin (BCG) vaccine more than a century ago, that a novel, efficacious TB vaccine is imminent. Here, we review recent data in the light of our current understanding of the immunology of TB infection and discuss the identification of biomarkers for vaccine efficacy and the next steps in the quest for an efficacious vaccine that can control the global TB epidemic.",
author = "Peter Andersen and Scriba, {Thomas J.}",
year = "2019",
doi = "10.1038/s41577-019-0174-z",
language = "English",
volume = "19",
pages = "550–562",
journal = "Nature Reviews. Immunology",
issn = "1474-1733",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Moving tuberculosis vaccines from theory to practice

AU - Andersen, Peter

AU - Scriba, Thomas J.

PY - 2019

Y1 - 2019

N2 - Tuberculosis (TB) vaccine research has reached a unique point in time. Breakthrough findings in both the basic immunology of Mycobacterium tuberculosis infection and the clinical development of TB vaccines suggest, for the first time since the discovery of the Mycobacterium bovis bacillus Calmette–Guérin (BCG) vaccine more than a century ago, that a novel, efficacious TB vaccine is imminent. Here, we review recent data in the light of our current understanding of the immunology of TB infection and discuss the identification of biomarkers for vaccine efficacy and the next steps in the quest for an efficacious vaccine that can control the global TB epidemic.

AB - Tuberculosis (TB) vaccine research has reached a unique point in time. Breakthrough findings in both the basic immunology of Mycobacterium tuberculosis infection and the clinical development of TB vaccines suggest, for the first time since the discovery of the Mycobacterium bovis bacillus Calmette–Guérin (BCG) vaccine more than a century ago, that a novel, efficacious TB vaccine is imminent. Here, we review recent data in the light of our current understanding of the immunology of TB infection and discuss the identification of biomarkers for vaccine efficacy and the next steps in the quest for an efficacious vaccine that can control the global TB epidemic.

U2 - 10.1038/s41577-019-0174-z

DO - 10.1038/s41577-019-0174-z

M3 - Review

C2 - 31114037

AN - SCOPUS:85066915288

VL - 19

SP - 550

EP - 562

JO - Nature Reviews. Immunology

JF - Nature Reviews. Immunology

SN - 1474-1733

ER -

ID: 226876802